1. Home
  2. DYNX vs SWKH Comparison

DYNX vs SWKH Comparison

Compare DYNX & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYNX
    SELLHOLDBUYas of 2024 years ago
  • SWKH
    SELLHOLDBUYas of 13 hours ago
  • Stock Information
  • Founded
  • DYNX 2024
  • SWKH 1996
  • Country
  • DYNX United States
  • SWKH United States
  • Employees
  • DYNX N/A
  • SWKH N/A
  • Industry
  • DYNX
  • SWKH Diversified Financial Services
  • Sector
  • DYNX
  • SWKH Finance
  • Exchange
  • DYNX NYSE
  • SWKH Nasdaq
  • Market Cap
  • DYNX 219.0M
  • SWKH 201.5M
  • IPO Year
  • DYNX 2024
  • SWKH 1999
  • Fundamental
  • Price
  • DYNX $9.79
  • SWKH $15.86
  • Analyst Decision
  • DYNX
  • SWKH
  • Analyst Count
  • DYNX 0
  • SWKH 0
  • Target Price
  • DYNX N/A
  • SWKH N/A
  • AVG Volume (30 Days)
  • DYNX 47.2K
  • SWKH 10.1K
  • Earning Date
  • DYNX 01-01-0001
  • SWKH 11-14-2024
  • Dividend Yield
  • DYNX N/A
  • SWKH N/A
  • EPS Growth
  • DYNX N/A
  • SWKH N/A
  • EPS
  • DYNX N/A
  • SWKH 0.84
  • Revenue
  • DYNX $2,124,981.00
  • SWKH $24,725,000.00
  • Revenue This Year
  • DYNX N/A
  • SWKH N/A
  • Revenue Next Year
  • DYNX N/A
  • SWKH $6.17
  • P/E Ratio
  • DYNX N/A
  • SWKH $19.03
  • Revenue Growth
  • DYNX N/A
  • SWKH N/A
  • 52 Week Low
  • DYNX $9.91
  • SWKH $15.14
  • 52 Week High
  • DYNX $9.98
  • SWKH $18.49
  • Technical
  • Relative Strength Index (RSI)
  • DYNX N/A
  • SWKH 43.28
  • Support Level
  • DYNX N/A
  • SWKH $15.63
  • Resistance Level
  • DYNX N/A
  • SWKH $16.41
  • Average True Range (ATR)
  • DYNX 0.00
  • SWKH 0.38
  • MACD
  • DYNX 0.00
  • SWKH -0.05
  • Stochastic Oscillator
  • DYNX 0.00
  • SWKH 18.11

Stock Price Comparison Chart: DYNX vs SWKH

DYNX
SWKH
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober02468101214161820DYNX VS SWKH

About DYNX DYNAMIX CORP

Dynamix Corp is a blank check company.

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use